Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2006-06-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor
cells and slow the growth of recurrent metastatic colorectal cancer.
PURPOSE: Randomized phase II trial to compare the effectiveness of two different doses of
gefitinib in treating patients who have recurrent metastatic colorectal cancer.